FZD1: As a Novel Prognostic Marker for Renal Clear Cell Carcinoma, is Associated with Tumor Immunoinfiltration

Renal clear cell carcinoma (ccRCC) is one of the most prevalent and aggressive histological subtypes of all renal cell carcinomas (RCCS) and is a metabolically abnormal cancer. Advanced ccRCC usually has a poor prognosis. Therefore, appropriate tumor markers need to be developed to predict the treatment, prognosis, and progression of ccRCC. Recombinant Frizzled Homolog 1 (FZD1) is a receptor for the Wnt signaling pathway, and overexpression of FZD1 has been detected in many cancer tissues and cells, leading to tumor development and drug resistance. However, its expression status and prognostic value in renal carcinoma remain unclear. Therefore, the purpose of this study was to explore the relationship between clinical features, overall survival, immune infiltration, and prognostic risk in patients with FZD1 and ccRCC through bioinformatics. ccRCC RNA-seq FPKM format data and clinical data were downloaded from TCGA database, and the correlation between FZD1 and ccRCC was evaluated by Cox and Logistic analysis. The results showed that the expression of FZD1 in renal carcinoma tissues was higher than that in normal tissues (P＜0.001); The ROC curve showed that FZD1 had high diagnostic value (AUC = 0.877). High expression of FZD1 is associated with immune status of renal clear cell carcinoma. These data indicate that the expression status of FZD1 has diagnostic and prognostic value in patients with ccRCC, and is a feasible potential novel prognostic marker for ccRCC, and may also be used as a potential therapeutic target for alleviating ccRCC patients.